Setback in Prostate Cancer Trial: CAPItello-280 Study for Truqap Discontinued
/in Clinical Trial, Metastatic, Phase 3/by MaxUPDATE: ATNM-400 a Promising Antibody Radioconjugate Delivering 225 Ac
/in Preclinical Research/by MaxOST11098: A Promising New Approach for Castration-Resistant Prostate Cancer
/in Preclinical Research/by MaxPhase 1 Trial: APG-5918 an EED Inhibitor for Prostate Cancer Therapy
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CTS2190 Targets Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial: SYN818 Shows Promise for Prostate Cancer Patients With HRR Genetic Mutations
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: NXP900 for Overcoming Resistance in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 48/2025 November 30, 2025
- Phase 1/2 Trial for MK-6070: A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers November 29, 2025
- UPDATE: Phase 1 GenSci143 Trial Set To Start By The End of December November 27, 2025
- Phase 2 Trial for The Combo Fasudil Hydrochloride Plus PD-1 Immune Checkpoint Blockade November 27, 2025